Effect of Bariatric Surgery on the Circulating Level of Adiponectin, Chemerin, Plasminogen Activator Inhibitor-1, Leptin, Resistin, and Visfatin: A Systematic Review and Meta-Analysis

 

 Permissions and Reprints

Abstract

Different adipokines secreted from adipose tissue, exert a range of physiological effects. The aim of present systematic review and meta-analysis was to critically investigate the consequence of bariatric surgery on circulating adipokines, that is, adiponectin, leptin, visfatin, resistin, plasminogen activator inhibitor, and chemerin. After systematically checking the following electronic databases: ISI web of Science, Scopus and PubMed without limitation in time and language up to February 2019, a pool based on a random effect model was established. Eighty-five eligible studies were entered for quantitative analysis. Our meta-analysis revealed that circulating adiponectin increased significantly after bariatric surgery [Standardized mean difference (SMD)=1.401, 95% CI: 1.101, 1.701, p<0.001]; whilst leptin (SMD=–2.178, 95% CI: –2.433, –1.923, p<0.001), PAI-1 (–14.928 ng/ml 95% CI: –21.794, –8.063, p<0.001), and chemerin (–50.238 ng/ml 95% CI: –85.708, –14.768, p<0.001) decreased. However, serum visfatin (2.05 ng/ml, 95% CI: –5.07, 9.17, p=0.573) and resistin (–2.080 ng/ml, 95% CI: –5.352, 1.192, p=0.21) were unchanged. In conclusion, bariatric surgery is associated with a reduction in specific adipokines including leptin, chemerin, and PAI-1, whereas adiponectin is raised, adaptations that could be indicative of improved fat mass and function.

• References

• 1 WHO Obesity and overweight. 2018 www.who.int
  PubMedGoogle Scholar
• 2 Steele CB, Thomas CC, Henley SJ. et al. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity – United States, 2005–2014. MMWR Morbidity Mortality Weekly Report 2017; 66: 1052-1058
  PubMedGoogle Scholar
• 3 Barnes AS. The epidemic of obesity and diabetes: Trends and treatments. Texas Heart Inst J 2011; 38: 142-144
  PubMedGoogle Scholar
• 4 Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes Targets Therap 2014; 7: 587-591
  PubMedGoogle Scholar
• 5 MacLean PS, Wing RR, Davidson T. et al. NIH working group report: Innovative research to improve maintenance of weight loss. Obesity (Silver Spring. Md) 2015; 23: 7-15
  PubMedGoogle Scholar
• 6 Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: Weight loss and bariatric surgery. Circul Res 2016; 118: 1844-1855
  CrossrefPubMedGoogle Scholar
• 7 Schigt A, Gerdes V, Cense H. et al. Bariatric surgery is an effective treatment for morbid obesity. Neth J Med 2013; 71: 4-9
  PubMedGoogle Scholar
• 8 Tham JC, Howes N, le Roux CW. The role of bariatric surgery in the treatment of diabetes. Ther Adv Chronic Dis 2014; 5: 149-157
  CrossrefPubMedGoogle Scholar
• 9 Xanthakos SA. Nutritional deficiencies in obesity and after bariatric surgery. Pediatr Clin North Am 2009; 56: 1105-1121
  CrossrefPubMedGoogle Scholar
• 10 Pessin JE, Kwon H. Adipokines mediate inflammation and insulin resistance. Front Endocrinol 2013; 4: 71
  PubMedGoogle Scholar
• 11 Bulcao C, Ferreira SR, Giuffrida FM. et al. The new adipose tissue and adipocytokines. Curr Diabetes Rev 2006; 2: 19-28
  CrossrefPubMedGoogle Scholar
• 12 Birbrair A, Zhang T, Wang Z-M. et al. Role of pericytes in skeletal muscle regeneration and fat accumulation. Stem Cells Develop 2013; 22: 2298-2314
  CrossrefPubMedGoogle Scholar
• 13 Smekal A, Vaclavik J. Adipokines and cardiovascular disease: A comprehensive review. Biomed Papers Med Faculty Univ Palacky, Olomouc, Czech 2017; 161: 31-40
  PubMedGoogle Scholar
• 14 Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol 2013; 4: 71
  PubMedGoogle Scholar
• 15 Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav 2014; 130: 157-169
  CrossrefPubMedGoogle Scholar
• 16 Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148: 293-300
  PubMedGoogle Scholar
• 17 Roh SG, Song SH, Choi KC. et al. Chemerin – a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007; 362: 1013-1018
  CrossrefPubMedGoogle Scholar
• 18 Sonoli SS, Shivprasad S, Prasad CV. et al. Visfatin – a review. Eur Rev Med Pharmacol Sci 2011; 15: 9-14
  PubMedGoogle Scholar
• 19 Jung RG, Motazedian P, Ramirez FD. et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis. Thromb J 2018; 16: 12
  CrossrefPubMedGoogle Scholar
• 20 Lazar MA. Resistin- and Obesity-associated metabolic diseases. Horm Metab Res 2007; 39: 710-716
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Busetto L, Perini P, Giantin V. et al. Relationship between energy expenditure and visceral fat accumulation in obese women submitted to adjustable silicone gastric banding (ASGB). Int J Obes Relat Metab Disord 1995; 19: 227-233
  PubMedGoogle Scholar
• 22 Serra A, Granada ML, Romero R. et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr (Edinburgh, Scotland) 2006; 25: 400-408
  CrossrefPubMedGoogle Scholar
• 23 Vendrell J, Broch M, Vilarrasa N. et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res 2004; 12: 962-971
  PubMedGoogle Scholar
• 24 Arica PC, Aydin S, Zengin U. et al. The Effects on obesity related peptides of laparoscopic gastric band applications in morbidly obese patients. J Invest Surg 2018; 31: 89-95
  CrossrefPubMedGoogle Scholar
• 25 De Luis DA, Izaola O, Conde R. et al. Visfatin levels in female, morbid, nondiabetic obese patients after biliopancreatic diversion surgery. Surg Obes Relat Dis 2011; 7: 195-198
  CrossrefPubMedGoogle Scholar
• 26 Engl J, Bobbert T, Ciardi C. et al. Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters. Obesity 2007; 15: 1172-1178
  CrossrefPubMedGoogle Scholar
• 27 Farey JE, Preda TC, Fisher OM. et al. Effect of laparoscopic sleeve gastrectomy on fasting gastrointestinal, pancreatic, and adipose-derived hormones and on non-esterified fatty acids. Obes Surg 2017; 27: 399-407
  CrossrefPubMedGoogle Scholar
• 28 Kotidis EV, Koliakos G, Papavramidis TS. et al. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: Is there a hormonal contribution to the weight-reducing effect of this procedure?. Obes Surg 2006; 16: 554-559
  CrossrefPubMedGoogle Scholar
• 29 Umeda LM, Pereira AZ, Carneiro G. et al. Postprandial adiponectin levels are associated with improvements in postprandial triglycerides after Roux-en-Y gastric bypass in type 2 diabetic patients. Metab Syndr Relat Disord 2013; 11: 343-348
  CrossrefPubMedGoogle Scholar
• 30 Whitson BA, Leslie DB, Kellogg TA. et al. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: A preliminary study. J Surg Res 2007; 142: 295-300
  CrossrefPubMedGoogle Scholar
• 31 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097
  CrossrefPubMedGoogle Scholar
• 32 Wells G, Shea B, O’connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Dept of Epidemiology and Community Medicine, University of Ottawa: Ottawa, Canada. 2011 www.ohri.ca
  PubMedGoogle Scholar
• 33 Wells G, Shea B, O’Connell D. et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011 www.ohri.ca
  PubMedGoogle Scholar
• 34 Borenstein M, Hedges LV, Higgins JP. et al. Introduction to Meta-analysis. New York: Wiley; 2011
  Google Scholar
• 35 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557
  CrossrefPubMedGoogle Scholar
• 36 Palmer TM, Sutton AJ, Peters JL. et al. Contour-enhanced funnel plots for meta-analysis. STATA J 2008; 8: 242-254
  PubMedGoogle Scholar
• 37 Adami GF, Cordera R, Andraghetti G. et al. Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. Obes Res 2004; 12: 684-687
  PubMedGoogle Scholar
• 38 Adami GF, Cordera R, Camerini G. et al. Long-term normalization of insulin sensitivity following biliopancreatic diversion for obesity. Int J Obes 2004; 28: 671-673
  CrossrefPubMedGoogle Scholar
• 39 Adami GF, Cordera R, Campostano A. et al. Serum leptin and weight loss in severely obese patients undergoing biliopancreatic diversion. Int J Obes 1998; 22: 822-824
  CrossrefPubMedGoogle Scholar
• 40 Adami GF, Gradaschi R, Andraghetti G. et al. Serum leptin and adiponectin concentration in type 2 diabetes patients in the short and long term following biliopancreatic diversion. Obes Surg 2016; 26: 2442-2448
  CrossrefPubMedGoogle Scholar
• 41 Alagna S, Cossu ML, Gallo P. et al. Biliopancreatic diversion: Long-term effects on gonadal function in severely obese men. Surg Obes Relat Dis 2006; 2: 82-86
  CrossrefPubMedGoogle Scholar
• 42 Alosco ML, Spitznagel MB, Strain G. et al. Improved serum leptin and ghrelin following bariatric surgery predict better postoperative cognitive function. J Clin Neurol (Korea) 2015; 11: 48-56
  CrossrefPubMedGoogle Scholar
• 43 Arismendi E, Rivas E, Agustí A. et al. The systemic inflammome of severe obesity before and after bariatric surgery. PLoS One 2014; 9: e107859
  CrossrefPubMedGoogle Scholar
• 44 Belligoli A, Sanna M, Serra R. et al. Incidence and predictors of hypoglycemia 1 year after laparoscopic sleeve gastrectomy. Obes Surg 2017; 27: 3179-3186
  CrossrefPubMedGoogle Scholar
• 45 Bobbioni-Harsch E, Morel P, Huber O. et al. Energy economy hampers body weight loss after gastric bypass. J Clin Endocrinol Metab 2000; 85: 4695-4700
  CrossrefPubMedGoogle Scholar
• 46 Brethauer SA, Heneghan HM, Eldar S. et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endoscop Intervent Tech 2011; 25: 2650-2659
  PubMedGoogle Scholar
• 47 Briatore L, Salani B, Andraghetti G. et al. Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion. Obesity 2008; 16: 77-81
  CrossrefPubMedGoogle Scholar
• 48 Bryant EJ, King NA, Falken Y. et al. Relationships among tonic and episodic aspects of motivation to eat, gut peptides, and weight before and after bariatric surgery. Surg Obes Relat Dis 2013; 9: 802-808
  CrossrefPubMedGoogle Scholar
• 49 Buzga M, Zavadilova V, Holeczy P. et al. Dietary intake and ghrelin and leptin changes after sleeve gastrectomy. Videosurg Miniinvas Tech 2014; 9: 554-561
  PubMedGoogle Scholar
• 50 Carroll JF, Franks SF, Smith AB. et al. Visceral adipose tissue loss and insulin resistance 6 months after laparoscopic gastric banding surgery: A preliminary study. Obes Surg 2009; 19: 47-55
  CrossrefPubMedGoogle Scholar
• 51 Catalan V, Gomez-Ambrosi J, Rodriguez A. et al. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-alpha stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis 2013; 9: 306-314
  CrossrefPubMedGoogle Scholar
• 52 Coupaye M, Bouillot JL, Coussieu C. et al. One-year changes in energy expenditure and serum leptin following adjustable gastric banding in obese women. Obes Surg 2005; 15: 827-833
  CrossrefPubMedGoogle Scholar
• 53 Das SK, Roberts SB, McCrory MA. et al. Long-term changes in energy expenditure and body composition after massive weight loss induced by gastric bypass surgery 1–4. Am J Clin Nutr 2003; 78: 22-30
  CrossrefPubMedGoogle Scholar
• 54 De La Torre NG, Rubio MA, Bordiú E. et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008; 93: 4276-4281
  CrossrefPubMedGoogle Scholar
• 55 De Marinis L, Bianchi A, Mancini A. et al. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: Relationships with insulin and body composition. J Clin Endocrinol Metab 2004; 89: 174-180
  CrossrefPubMedGoogle Scholar
• 56 Gannage-Yared MH, Yaghi C, Habre B. et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: Results from both cross-sectional and interventional study. Eur J Endocrinol 2008; 158: 353-359
  CrossrefPubMedGoogle Scholar
• 57 García-Fuentes E, García-Almeida JM, García-Arnés J. et al. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity 2007; 15: 2391-2395
  CrossrefPubMedGoogle Scholar
• 58 Garcia-Unzueta MT, Fernandez-Santiago R, Dominguez-Diez A. et al. Fasting plasma ghrelin levels increase progressively after biliopancreatic diversion: One-year follow-up. Obes Surg 2005; 15: 187-190
  CrossrefPubMedGoogle Scholar
• 59 Guglielmi V, Bellia A, Gentileschi P. et al. Parathyroid hormone in surgery-induced weight loss: No glucometabolic effects but potential adaptive response to skeletal loading. Endocrine 2018; 59: 288-295
  CrossrefPubMedGoogle Scholar
• 60 Guldstrand M, Backman L, Adamson U. et al. Lowering of circulating insulin and leptin is closely associated following weight reduction after vertical banded gastroplasty in obese women. Diabetes Obes Metab 1999; 1: 53-55
  CrossrefPubMedGoogle Scholar
• 61 Haider DG, Schindler K, Schaller G. et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581
  CrossrefPubMedGoogle Scholar
• 62 Haluzikova D, Lacinova Z, Kavalkova P. et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring. Md) 2013; 21: 1335-1342
  PubMedGoogle Scholar
• 63 Handisurya A, Riedl M, Vila G. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg 2010; 20: 198-203
  CrossrefPubMedGoogle Scholar
• 64 Hanusch-Enserer U, Cauza E, Brabant G. et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab 2004; 89: 3352-3358
  CrossrefPubMedGoogle Scholar
• 65 Hanusch-Enserer U, Zorn G, Wojta J. et al. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J 2009; 30: 1516-1524
  CrossrefPubMedGoogle Scholar
• 66 Heinonen MV, Purhonen AK, Miettinen P. et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regulat Pept 2005; 130: 7-13
  CrossrefPubMedGoogle Scholar
• 67 Holdstock C, Engstrom BE, Ohrvall M. et al. Ghrelin and adipose tissue regulatory peptides: Effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88: 3177-3183
  CrossrefPubMedGoogle Scholar
• 68 Joao Cabrera E, Valezi AC, Delfino VD. et al. Reduction in plasma levels of inflammatory and oxidative stress indicators after Roux-en-Y gastric bypass. Obes Surg 2010; 20: 42-49
  CrossrefPubMedGoogle Scholar
• 69 Korner J, Inabnet W, Febres G. et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes 2009; 33: 786-795
  CrossrefPubMedGoogle Scholar
• 70 Krieger AC, Youn H, Modersitzki F. et al. Effects of laparoscopic adjustable gastric banding on sleep and metabolism: A 12-month follow-up study. Int J Gen Med 2012; 5: 975-981
  PubMedGoogle Scholar
• 71 Laimer M, Ebenbichler CF, Kaser S. et al. Weight loss increases soluble leptin receptor levels and the soluble receptor bound fraction of leptin. Obes Res 2002; 10: 597-601
  PubMedGoogle Scholar
• 72 Lambert G, Lima MMO, Felici AC. et al. Early regression of carotid intima-media thickness after bariatric surgery and its relation to serum leptin reduction. Obes Surg 2018; 28: 226-233
  CrossrefPubMedGoogle Scholar
• 73 Lima MM, Pareja JC, Alegre SM. et al. Acute effect of roux-en-y gastric bypass on whole-body insulin sensitivity: A study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 2010; 95: 3871-3875
  CrossrefPubMedGoogle Scholar
• 74 Lin E, Phillips LS, Ziegler TR. et al. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight lossIncreases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes 2007; 56: 735-742
  CrossrefPubMedGoogle Scholar
• 75 Liou JM, Lin JT, Lee WJ. et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg 2008; 18: 84-89
  CrossrefPubMedGoogle Scholar
• 76 Magkos F, Fabbrini E, McCrea J. et al. Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin. Diabetes Obes Metab 2010; 12: 584-590
  PubMedGoogle Scholar
• 77 Manco M, Fernandez-Real JM, Valera-Mora ME. et al. Massive weight loss decreases corticosteroid-binding globulin levels and increases free cortisol in healthy obese patients: An adaptive phenomenon?. Diabetes Care 2007; 30: 1494-1500
  CrossrefPubMedGoogle Scholar
• 78 Marantos G, Daskalakis M, Karkavitsas N. et al. Changes in metabolic profile and adipoinsular axis in morbidly obese premenopausal females treated with restrictive bariatric surgery. World J Surg 2011; 35: 2022-2023
  CrossrefPubMedGoogle Scholar
• 79 Mazidi M, Gao HK, Li L. et al. Changes in inflammatory and cardiometabolic profile after Roux-en-Y gastric bypass: A prospective study in an overweight chinese cohort. Bariatr Surg Pract Patient Care 2017; 12: 45-48
  PubMedGoogle Scholar
• 80 Molin Netto BD, Earthman CP, Cravo Bettini S. et al. Early effects of Roux-en-Y gastric bypass on peptides and hormones involved in the control of energy balance. Eur J Gastroenterol Hepatol 2016; 28: 1050-1055
  CrossrefPubMedGoogle Scholar
• 81 Mora M, Aranda GB, De Hollanda A. et al. Weight loss is a major contributor to improved sexual function after bariatric surgery. Surg Endosc Intervent Tech 2013; 27: 3197-3204
  PubMedGoogle Scholar
• 82 Navaneethan SD, Kelly KR, Sabbagh F. et al. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg 2010; 20: 308-315
  CrossrefPubMedGoogle Scholar
• 83 Nijhuis J, van Dielen FM, Buurman WA. et al. Ghrelin, leptin and insulin levels after restrictive surgery: A 2-year follow-up study. Obes Surg 2004; 14: 783-787
  CrossrefPubMedGoogle Scholar
• 84 Olmos JM, Vazquez LA, Amado JA. et al. Mineral metabolism in obese patients following vertical banded gastroplasty. Obes Surg 2008; 18: 197-203
  CrossrefPubMedGoogle Scholar
• 85 Perathoner A, Weißenbacher A, Sucher R. et al. Significant weight loss and rapid resolution of diabetes and dyslipidemia during short-term follow-up after laparoscopic sleeve gastrectomy. Obes Surg 2013; 23: 1966-1972
  CrossrefPubMedGoogle Scholar
• 86 Pérez-Romero N, Serra A, Granada ML. et al. Effects of two variants of Roux-en-Y gastric bypass on metabolism behaviour: Focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg 2010; 20: 600-609
  CrossrefPubMedGoogle Scholar
• 87 Raftopoulos I, Bernstein B, O’Hara K. et al. Protein intake compliance of morbidly obese patients undergoing bariatric surgery and its effect on weight loss and biochemical parameters. Surg Obes Relat Dis 2011; 7: 733-742
  CrossrefPubMedGoogle Scholar
• 88 Terra X, Auguet T, Guiu-Jurado E. et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg 2013; 23: 1790-1798
  CrossrefPubMedGoogle Scholar
• 89 Tschoner A, Sturm W, Engl J. et al. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr Metab Cardiovasc Dis 2012; 22: 340-346
  CrossrefPubMedGoogle Scholar
• 90 Urbanavičius V, Abalikšta T, Brimas G. et al. Comparison of changes in blood glucose, insulin resistance indices, and adipokine levels in diabetic and nondiabetic subjects with morbid obesity after laparoscopic adjustable gastric banding. Medicina (Lithuania) 2013; 49: 9-14
  CrossrefPubMedGoogle Scholar
• 91 Yadav R, Hama S, Liu Y. et al. Effect of Roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vascular inflammation in obesity and diabetes. Front Immunol 2017; 8: 1512
  CrossrefPubMedGoogle Scholar
• 92 Bachmayer C, Lammert A, Hasenberg T. et al. Healthy obese and post bariatric patients – Metabolic and vascular patterns. Exp Clin Endocrinol Diabetes 2013; 121: 483-487
  Article in Thieme ConnectPubMedGoogle Scholar
• 93 Broch M, Gomez JM, Auguet MT. et al. Association of retinol-binding protein-4 (RBP4) with lipid parameters in obese women. Obes Surg 2010; 20: 1258-1264
  CrossrefPubMedGoogle Scholar
• 94 Carrasco F, Basfi-Fer K, Rojas P. et al. Changes in bone mineral density after sleeve Gastrectomy or gastric bypass: Relationships with variations in vitamin D, ghrelin, and adiponectin levels. Obes Surg 2014; 24: 877-884
  CrossrefPubMedGoogle Scholar
• 95 Couce ME, Cottam D, Esplen J. et al. Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer. Obes Surg 2006; 16: 870-878
  CrossrefPubMedGoogle Scholar
• 96 Coughlin CC, Finck BN, Eagon JC. et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring. Md) 2007; 15: 640-645
  PubMedGoogle Scholar
• 97 de Luis DA, Pacheco D, Aller R. et al. Influence of G308A polymorphism of tumor necrosis factor alpha gene on surgical results of biliopancreatic diversion. Obes Surg 2010; 20: 221-225
  CrossrefPubMedGoogle Scholar
• 98 Domienik-Karlowicz J, Rymarczyk Z, Dzikowska-Diduch O. et al. Emerging markers of atherosclerosis before and after bariatric surgery. Obes Surg 2015; 25: 486-493
  CrossrefPubMedGoogle Scholar
• 99 Fellici AC, Lambert G, Lima MM. et al. Surgical treatment of type 2 diabetes in subjects with mild obesity: Mechanisms underlying metabolic improvements. Obes Surg 2015; 25: 36-44
  CrossrefPubMedGoogle Scholar
• 100 Hosseinzadeh-Attar MJ, Golpaie A, Janani L. et al. Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects. Obes Facts 2013; 6: 193-202
  CrossrefPubMedGoogle Scholar
• 101 Illan-Gomez F, Gonzalvez-Ortega M, Orea-Soler I. et al. Obesity and inflammation: Change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 2012; 22: 950-955
  CrossrefPubMedGoogle Scholar
• 102 Kopp HP, Krzyzanowska K, Mohlig M. et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes 2005; 29: 766-771
  CrossrefPubMedGoogle Scholar
• 103 Lammert A, Hasenberg T, Kraupner C. et al. Improved arteriole-to-venule ratio of retinal vessels resulting from bariatric surgery. Obesity (Silver Spring. Md) 2012; 20: 2262-2267
  PubMedGoogle Scholar
• 104 Linscheid P, Christ-Crain M, Stoeckli R. et al. Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss. Diabetes Obes Metab 2008; 10: 1266-1270
  PubMedGoogle Scholar
• 105 Schmatz R, Zanini D, Gutierres JM. et al. Evaluation of the biochemical, inflammatory and oxidative profile of obese patients given clinical treatment and bariatric surgery. Clin Chim Acta 2017; 465: 72-79
  CrossrefPubMedGoogle Scholar
• 106 Tirado R, Masdeu MJ, Vigil L. et al. Impact of bariatric surgery on heme oxygenase-1, inflammation, and insulin resistance in morbid obesity with obstructive sleep apnea. Obes Surg 2017; 27: 2338-2346
  CrossrefPubMedGoogle Scholar
• 107 De Luis DA, Terroba MC, Cuellar L. et al. Resistin levels in morbid obese patients following the biliopancreatic diversion surgery. Horm Metab Res 2011; 43: 205-208
  Article in Thieme ConnectPubMedGoogle Scholar
• 108 Auguet T, Terra X, Hernández M. et al. Clinical and adipocytokine changes after bariatric surgery in morbidly obese women. Obesity 2014; 22: 188-194
  CrossrefPubMedGoogle Scholar
• 109 Botella-Carretero JI, Luque-Ramirez M, Alvarez-Blasco F. et al. The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery. Obes Surg 2008; 18: 1000-1006
  CrossrefPubMedGoogle Scholar
• 110 Baena-Fustegueras JA, Pardina E, Balada E. et al. Soluble CD40 ligand in morbidly obese patients: effect of body mass index on recovery to normal levels after gastric bypass surgery. JAMA Surg 2013; 148: 151-156
  CrossrefPubMedGoogle Scholar
• 111 Kim MK, Jang EH, Hong OK. et al. Changes in serum levels of bone morphogenic protein 4 and inflammatory cytokines after bariatric surgery in severely obese Korean patients with type 2 diabetes. Int J Endocrinol 2013; 681205
  PubMedGoogle Scholar
• 112 Parlee SD, Wang Y, Poirier P. et al. Biliopancreatic diversion with duodenal switch modifies plasma chemerin in early and late post-operative periods. Obesity 2015; 23: 1201-1208
  CrossrefPubMedGoogle Scholar
• 113 Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703
  CrossrefPubMedGoogle Scholar
• 114 Achari A, Jain S. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 2017; 18: 1321
  CrossrefPubMedGoogle Scholar
• 115 Hotta K, Funahashi T, Arita Y. et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosc Thromb Vascul Biol 2000; 20: 1595-1599
  PubMedGoogle Scholar
• 116 Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes 2009; 32: S13
  PubMedGoogle Scholar
• 117 Combs TP, Wagner JA, Berger J. et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007
  CrossrefPubMedGoogle Scholar
• 118 Phillips SA, Ciaraldi TP, Kong AP. et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52: 667674
  PubMedGoogle Scholar
• 119 Xu A, Wang H, Hoo RL. et al. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology 2009; 150: 625-633
  CrossrefPubMedGoogle Scholar
• 120 Mohammadi A, Gholamhoseinian A, Fallah H. Zataria multiflora increases insulin sensitivity and PPARγ gene expression in high fructose fed insulin resistant rats. Iran J Basic Med Sci 2014; 17: 263
  PubMedGoogle Scholar
• 121 Jürimäe J, Hofmann P, Jürimäe T. et al. Plasma adiponectin response to sculling exercise at individual anaerobic threshold in college level male rowers. Int J Sports Med 2006; 27: 272-277
  Article in Thieme ConnectPubMedGoogle Scholar
• 122 Jürimäe J, Purge P, Jürimäe T. Adiponectin is altered after maximal exercise in highly trained male rowers. Eur J Appl Physiol 2005; 93: 502-505
  CrossrefPubMedGoogle Scholar
• 123 Kriketos AD, Gan SK, Poynten AM. et al. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004; 27: 629-630
  CrossrefPubMedGoogle Scholar
• 124 Geagea AG, Mallat S, Matar CF. et al. Adiponectin and inflammation in health and disease: An update. Open Med J. 2018 5. Publisher Id: MEDJ-5-20 DOI: 10.2174/1874220301805010020
  PubMedGoogle Scholar
• 125 Kelesidis T, Kelesidis I, Chou S. et al. Narrative review: The role of leptin in human physiology: Emerging clinical applications. Ann Inter Med 2010; 152: 93-100
  CrossrefPubMedGoogle Scholar
• 126 Paz-Filho G, Mastronardi C, Franco CB. et al. Leptin: Molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arquiv Brasil. Endocrinol Metab 2012; 56: 597-607
  PubMedGoogle Scholar
• 127 Pan WW, Myers MG. Leptin and the maintenance of elevated body weight. Nat. Rev Neurosci 2018; 19: 95
  PubMedGoogle Scholar
• 128 Facey A, Dilworth L, Irving R. A review of the leptin hormone and the association with obesity and diabetes mellitus. J Diabetes Metab 2017; 8 DOI: 10.4172/2155-6156.1000727
  PubMedGoogle Scholar
• 129 Fontes-Villalba M, Lindeberg S, Granfeldt Y. et al. Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: A randomised cross-over trial. Cardiovasc Diabetol 2016; 15: 80
  CrossrefPubMedGoogle Scholar
• 130 Somodi S, Seres I, Lőrincz H. et al. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int J Endocrinol. 2018: 9596054. doi: 10.1155/2018/9596054 eCollection 2018
  PubMedGoogle Scholar
• 131 Kruithof EK, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988; 59: 007-012
  Article in Thieme ConnectPubMedGoogle Scholar
• 132 Chen R, Yan J, Liu P. et al. Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke. Metab Brain Dis 2017; 32: 667-673
  CrossrefPubMedGoogle Scholar
• 133 Lerman RH, Desai A, Lamb JJ. et al. A phytochemical-rich multivitamin-multimineral supplement is bioavailable and reduces serum oxidized low-density lipoprotein, myeloperoxidase, and plasminogen activator inhibitor-1 in a four-week pilot trial of healthy individuals. Glob Adv Health Med 2014; 3: 34-39
  CrossrefPubMedGoogle Scholar
• 134 Jamaluddin MS, Weakley SM, Yao Q. et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165: 622-632
  CrossrefPubMedGoogle Scholar
• 135 McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol 2006; 17: 170-175
  CrossrefPubMedGoogle Scholar
• 136 Chang YH, Chang DM, Lin KC. et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-527
  CrossrefPubMedGoogle Scholar
• 137 Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012; 6: 120-124
  CrossrefPubMedGoogle Scholar
• 138 Ferland DJ, Watts SW. Chemerin: A comprehensive review elucidating the need for cardiovascular research. Pharmacol Res 2015; 99: 351-361
  CrossrefPubMedGoogle Scholar
• 139 Roman AA, Parlee SD, Sinal CJ. Chemerin: A potential endocrine link between obesity and type 2 diabetes. Endocrine 2012; 42: 243-251
  CrossrefPubMedGoogle Scholar
• 140 Helfer G, Wu QF. Chemerin: A multifaceted adipokine involved in metabolic disorders. J Endocrinol 2018; 238: R79-R94
  CrossrefPubMedGoogle Scholar

• Supplementary Material